Leiomyosarcoma (LMS) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Leiomyosarcoma (LMS) is a rare form of cancer that most commonly affects the uterus but also affects other areas such as the bladder or gastrointestinal system. It is designated a “soft tissue sarcoma” and originates in the smooth or involuntary muscle. LMS is considered cancer and is different from benign leiomyoma. LMS is considered “treatable” when caught early.

Etiology-

The exact cause of leiomyosarcoma is unknown. Researchers speculate that genetic factors may play a contributing role in causing LMS.

In individuals with cancer, including leiomyosarcoma, malignancies may develop due to abnormal changes in the structure and orientation of specific cells known as oncogenes or tumor suppressor genes. Oncogenes control cell growth; tumor suppressor genes control cell division and ensure that cells die correctly. The exact cause of changes to these genes is unknown.

Epidemiology-

According to the American Cancer Society, at least 15,000 new cases of soft tissue sarcoma occur each year in the U.S. Soft tissue sarcomas affect men and women equally and occur more often in adults than children or adolescents. Soft tissue sarcomas account for 1 percent of all adult cancers in the U.S. According to one estimate, leiomyosarcomas account for 7-11 percent of all cases of soft tissue sarcomas.

The competitive landscape of Leiomyosarcoma (LMS) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Leiomyosarcoma (LMS) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Leiomyosarcoma (LMS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Leiomyosarcoma (LMS) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          trabectedin        PharmaMar       Phase 2

2          TTI-621 and Doxorubicin            Trillium Therapeutics Inc.            Phase 1/2

3          PTC596 and Dacarbazine          PTC Therapeutics         Phase 1

4          Trabectedin       Xian-Janssen Pharmaceutical Ltd.         Phase 3

5          Dinutuximab Beta, Zoledronic acid, Interleukin-2 EUSA Pharma, Inc.            Phase 2

6          Lurbinectedin and Doxorubicin   Jazz Pharmaceuticals    Phase 1/2

7          Rucaparib and Nivolumab          Clovis Oncology, Inc.     Phase 2

8          Avelumab and Gemcitabine       Merck KGaA, Darmstadt, Germany            Phase 2

9          AL3818 Advenchen Laboratories, LLC    Phase 3

10        Itacitinib            Incyte Corporation         Phase 1

Continued